Dr. Ellis Discusses the Cell-Proliferation Marker Ki67

Matthew J. Ellis, MD, PhD
Published: Wednesday, Aug 24, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses the cell-proliferation marker Ki67.

Ellis explains that the marker has been examined for many years because of its ability to show how many tumor cells are actively committed to cell division. An overexpression of Ki67 generally translates into a more aggressive clinical course. Despite this evidence there currently are not any guidelines or evidence to support testing for the marker in every tumor.
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses the cell-proliferation marker Ki67.

Ellis explains that the marker has been examined for many years because of its ability to show how many tumor cells are actively committed to cell division. An overexpression of Ki67 generally translates into a more aggressive clinical course. Despite this evidence there currently are not any guidelines or evidence to support testing for the marker in every tumor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x